Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Phase 4.
Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Phase 4.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Yoshifumi Saisho. Alogliptin benzoate for management of type 2 diabetes. Vasc Health Risk Manag. 2015; 11: 229–243. Published online 2015 Apr 10. doi: 10.2147/VHRM.S68564
[2] Bethany P Cummings,et al. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. J Endocrinol. Author manuscript; available in PMC 2015 Jun 5.Published in final edited form as: J Endocrinol. 2014 Apr; 221(1): 133–144. Published online 2014 Mar 13. doi: 10.1530/JOE-13-0601.
分子式 C18H21N5O2 |
分子量 339.39 |
CAS号 850649-61-5 |
储存方式 -20 ℃长期冷藏储存。冰袋运输 |
溶剂(常温) |
DMSO 64 mg/mL |
Water 1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
0.5% methylcellulose 30 mg/mL
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们